| Year |
Citation |
Score |
| 2024 |
Tosh DK, Pavan M, Cronin C, Pottie E, Wan TC, Chen E, Lewicki SA, Campbell RG, Gao ZG, Auchampach JA, Stove CP, Liang BT, Jacobson KA. 2-Substituted (N)-Methanocarba A Adenosine Receptor Agonists: In Silico, In Vitro, and In Vivo Characterization. Acs Pharmacology & Translational Science. 7: 2154-2173. PMID 39022354 DOI: 10.1021/acsptsci.4c00223 |
0.51 |
|
| 2024 |
Pradhan B, Pavan M, Fisher CL, Salmaso V, Wan TC, Keyes RF, Rollison N, Suresh RR, Kumar TS, Gao ZG, Smith BC, Auchampach JA, Jacobson KA. Lipid Trolling to Optimize A Adenosine Receptor-Positive Allosteric Modulators (PAMs). Journal of Medicinal Chemistry. PMID 38959401 DOI: 10.1021/acs.jmedchem.4c00944 |
0.402 |
|
| 2024 |
Fisher CL, Pavan M, Salmaso V, Keyes RF, Wan TC, Pradhan B, Gao ZG, Smith BC, Jacobson KA, Auchampach JA. Extrahelical binding site for a 1-imidazo[4,5-c]quinolin-4-amine A adenosine receptor positive allosteric modulator on helix 8 and distal portions of transmembrane domains 1 and 7. Molecular Pharmacology. PMID 38182432 DOI: 10.1124/molpharm.123.000784 |
0.402 |
|
| 2023 |
Tosh DK, Fisher CL, Salmaso V, Wan TC, Campbell RG, Chen E, Gao ZG, Auchampach JA, Jacobson KA. First Potent Macrocyclic A Adenosine Receptor Agonists Reveal G-Protein and β-Arrestin2 Signaling Preferences. Acs Pharmacology & Translational Science. 6: 1288-1305. PMID 37705595 DOI: 10.1021/acsptsci.3c00126 |
0.501 |
|
| 2022 |
Gao ZG, Auchampach JA, Jacobson KA. Species dependence of A adenosine receptor pharmacology and function. Purinergic Signalling. 1-28. PMID 36538251 DOI: 10.1007/s11302-022-09910-1 |
0.46 |
|
| 2022 |
Fallot LB, Suresh RR, Fisher CL, Salmaso V, O'Connor RD, Kaufman N, Gao ZG, Auchampach JA, Jacobson KA. Structure-Activity Studies of 1-Imidazo[4,5-]quinolin-4-amine Derivatives as A Adenosine Receptor Positive Allosteric Modulators. Journal of Medicinal Chemistry. 65: 15238-15262. PMID 36367749 DOI: 10.1021/acs.jmedchem.2c01170 |
0.435 |
|
| 2022 |
Fisher CL, Fallot LB, Wan TC, Keyes RF, Suresh RR, Rothwell AC, Gao ZG, McCorvy JD, Smith BC, Jacobson KA, Auchampach JA. Characterization of Dual-Acting A Adenosine Receptor Positive Allosteric Modulators That Preferentially Enhance Adenosine-Induced Gα and Gα Isoprotein Activation. Acs Pharmacology & Translational Science. 5: 625-641. PMID 35983277 DOI: 10.1021/acsptsci.2c00076 |
0.458 |
|
| 2021 |
Tosh DK, Salmaso V, Campbell RG, Rao H, Bitant A, Pottie E, Stove CP, Liu N, Gavrilova O, Gao ZG, Auchampach JA, Jacobson KA. A adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity. European Journal of Medicinal Chemistry. 113983. PMID 34844790 DOI: 10.1016/j.ejmech.2021.113983 |
0.47 |
|
| 2020 |
Tosh DK, Salmaso V, Rao H, Campbell R, Bitant A, Gao ZG, Auchampach JA, Jacobson KA. Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as A Receptor Agonists. Acs Medicinal Chemistry Letters. 11: 1935-1941. PMID 33062176 DOI: 10.1021/Acsmedchemlett.9B00637 |
0.452 |
|
| 2020 |
Tosh DK, Salmaso V, Rao H, Bitant A, Fisher CL, Lieberman DI, Vorbrüggen H, Reitman ML, Gavrilova O, Gao ZG, Auchampach JA, Jacobson KA. Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A Adenosine Receptors: Affinity Enhancement by -(2-Phenylethyl) Substitution. Journal of Medicinal Chemistry. PMID 32271569 DOI: 10.1021/acs.jmedchem.0c00235 |
0.508 |
|
| 2019 |
Wan TC, Tampo A, Kwok WM, Auchampach JA. Ability of CP-532,903 to protect mouse hearts from ischemia/reperfusion injury is dependent on expression of A adenosine receptors in cardiomyoyctes. Biochemical Pharmacology. PMID 30710517 DOI: 10.1016/J.Bcp.2019.01.022 |
0.318 |
|
| 2019 |
Tosh DK, Rao H, Bitant A, Salmaso V, Mannes P, Lieberman DI, Vaughan KL, Mattison JA, Rothwell AC, Auchampach JA, Ciancetta A, Liu N, Cui Z, Gao ZG, Reitman ML, et al. Design and in Vivo Characterization of A Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series. Journal of Medicinal Chemistry. PMID 30605331 DOI: 10.1021/acs.jmedchem.8b01662 |
0.503 |
|
| 2018 |
Yu J, Mannes P, Jung YH, Ciancetta A, Bitant A, Lieberman DI, Khaznadar S, Auchampach JA, Gao ZG, Jacobson KA. Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A adenosine receptor antagonists. Medchemcomm. 9: 1920-1932. PMID 30568760 DOI: 10.1039/C8Md00317C |
0.502 |
|
| 2018 |
Tosh DK, Ciancetta A, Mannes P, Warnick E, Janowsky A, Eshleman AJ, Gizewski E, Brust TF, Bohn LM, Auchampach JA, Gao ZG, Jacobson KA. Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists. Acs Omega. 3: 12658-12678. PMID 30411015 DOI: 10.1021/acsomega.8b01237 |
0.498 |
|
| 2018 |
Carlin JL, Jain S, Duroux R, Suresh RR, Xiao C, Auchampach JA, Jacobson KA, Gavrilova O, Reitman ML. Activation of adenosine Aor Areceptors causes hypothermia in mice. Neuropharmacology. PMID 29548686 DOI: 10.1016/J.Neuropharm.2018.02.035 |
0.536 |
|
| 2017 |
Duroux R, Ciancetta A, Mannes P, Yu J, Boyapati S, Gizewski E, Yous S, Ciruela F, Auchampach JA, Gao ZG, Jacobson KA. Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine functionalized congeners. Medchemcomm. 8: 1659-1667. PMID 29250307 DOI: 10.1039/C7Md00247E |
0.461 |
|
| 2017 |
Du L, Gao ZG, Paoletta S, Wan TC, Gizewski ET, Barbour S, van Veldhoven JPD, IJzerman AP, Jacobson KA, Auchampach JA. Species differences and mechanism of action of A3 adenosine receptor allosteric modulators. Purinergic Signalling. PMID 29170977 DOI: 10.1007/S11302-017-9592-1 |
0.509 |
|
| 2017 |
Tosh DK, Janowsky A, Eshleman AJ, Warnick E, Gao ZG, Chen Z, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA. Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters. Journal of Medicinal Chemistry. PMID 28319392 DOI: 10.1021/Acs.Jmedchem.7B00141 |
0.442 |
|
| 2017 |
Densmore JC, Schaid TR, Jeziorczak PM, Medhora M, Audi S, Nayak S, Auchampach J, Dwinell MR, Geurts AM, Jacobs ER. Lung injury pathways: Adenosine receptor 2B signaling limits development of ischemic bronchiolitis obliterans organizing pneumonia. Experimental Lung Research. 1-11. PMID 28266889 DOI: 10.1080/01902148.2017.1286697 |
0.345 |
|
| 2016 |
Carlin JL, Jain S, Gizewski E, Wan TC, Tosh DK, Xiao C, Auchampach JA, Jacobson KA, Gavrilova O, Reitman ML. Hypothermia in mouse is caused by adenosine A1 and A3 receptor agonists and AMP via three distinct mechanisms. Neuropharmacology. PMID 27914963 DOI: 10.1016/J.Neuropharm.2016.11.026 |
0.554 |
|
| 2016 |
Fisher JB, Horst A, Wan T, Kim MS, Auchampach J, Lough J. Depletion of Tip60 from In Vivo Cardiomyocytes Increases Myocyte Density, Followed by Cardiac Dysfunction, Myocyte Fallout and Lethality. Plos One. 11: e0164855. PMID 27768769 DOI: 10.1371/Journal.Pone.0164855 |
0.31 |
|
| 2016 |
Tosh DK, Ciancetta A, Warnick E, O'Connor R, Chen Z, Gizewski E, Crane S, Gao ZG, Auchampach JA, Salvemini D, Jacobson KA. Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists. Journal of Medicinal Chemistry. PMID 26890707 DOI: 10.1021/Acs.Jmedchem.5B01998 |
0.47 |
|
| 2015 |
Nayak S, Khan MA, Wan TC, Pei H, Linden J, Dwinell MR, Geurts AM, Imig JD, Auchampach JA. Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension. Purinergic Signalling. PMID 26385692 DOI: 10.1007/S11302-015-9470-7 |
0.3 |
|
| 2015 |
Tosh DK, Paoletta S, Chen Z, Crane S, Lloyd J, Gao ZG, Gizewski ET, Auchampach JA, Salvemini D, Jacobson KA. Structure-Based Design, Synthesis by Click Chemistry and in Vivo Activity of Highly Selective A3 Adenosine Receptor Agonists. Medchemcomm. 6: 555-563. PMID 26236460 DOI: 10.1039/C4Md00571F |
0.478 |
|
| 2015 |
Tosh DK, Crane S, Chen Z, Paoletta S, Gao ZG, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA. Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy. Acs Medicinal Chemistry Letters. 6: 804-8. PMID 26191370 DOI: 10.1021/Acsmedchemlett.5B00150 |
0.501 |
|
| 2014 |
Tosh DK, Finley A, Paoletta S, Moss SM, Gao ZG, Gizewski ET, Auchampach JA, Salvemini D, Jacobson KA. In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists. Journal of Medicinal Chemistry. 57: 9901-14. PMID 25422861 DOI: 10.1021/Jm501021N |
0.472 |
|
| 2014 |
Lakshmikanthan S, Zieba BJ, Ge ZD, Momotani K, Zheng X, Lund H, Artamonov MV, Maas JE, Szabo A, Zhang DX, Auchampach JA, Mattson DL, Somlyo AV, Chrzanowska-Wodnicka M. Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure. Arteriosclerosis, Thrombosis, and Vascular Biology. 34: 1486-94. PMID 24790136 DOI: 10.1161/Atvbaha.114.303678 |
0.739 |
|
| 2013 |
Paoletta S, Tosh DK, Finley A, Gizewski ET, Moss SM, Gao ZG, Auchampach JA, Salvemini D, Jacobson KA. Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. Journal of Medicinal Chemistry. 56: 5949-63. PMID 23789857 DOI: 10.1021/Jm4007966 |
0.475 |
|
| 2013 |
Kozma E, Gizewski ET, Tosh DK, Squarcialupi L, Auchampach JA, Jacobson KA. Characterization by flow cytometry of fluorescent, selective agonist probes of the A(3) adenosine receptor. Biochemical Pharmacology. 85: 1171-81. PMID 23376019 DOI: 10.1016/J.Bcp.2013.01.021 |
0.474 |
|
| 2013 |
Chandrasekera PC, Wan TC, Gizewski ET, Auchampach JA, Lasley RD. Adenosine A1 receptors heterodimerize with β1- and β2-adrenergic receptors creating novel receptor complexes with altered G protein coupling and signaling. Cellular Signalling. 25: 736-42. PMID 23291003 DOI: 10.1016/j.cellsig.2012.12.022 |
0.316 |
|
| 2012 |
Tosh DK, Deflorian F, Phan K, Gao ZG, Wan TC, Gizewski E, Auchampach JA, Jacobson KA. Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. Journal of Medicinal Chemistry. 55: 4847-60. PMID 22559880 DOI: 10.1021/Jm300396N |
0.5 |
|
| 2012 |
Du L, Gao ZG, Nithipatikom K, Ijzerman AP, Veldhoven JP, Jacobson KA, Gross GJ, Auchampach JA. Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor. The Journal of Pharmacology and Experimental Therapeutics. 340: 210-7. PMID 22011434 DOI: 10.1124/Jpet.111.187559 |
0.512 |
|
| 2011 |
Wan TC, Tosh DK, Du L, Gizewski ET, Jacobson KA, Auchampach JA. Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts. Bmc Pharmacology. 11: 11. PMID 22039965 DOI: 10.1186/1471-2210-11-11 |
0.544 |
|
| 2011 |
van der Hoeven D, Wan TC, Gizewski ET, Kreckler LM, Maas JE, Van Orman J, Ravid K, Auchampach JA. A role for the low-affinity A2B adenosine receptor in regulating superoxide generation by murine neutrophils. The Journal of Pharmacology and Experimental Therapeutics. 338: 1004-12. PMID 21693629 DOI: 10.1124/Jpet.111.181792 |
0.743 |
|
| 2011 |
Auchampach JA, Maas JE, Wan TC, Figler RA, Gross GJ. Are we putting too much stock in mice? Journal of Molecular and Cellular Cardiology. 50: 584-5. PMID 21129379 DOI: 10.1016/J.Yjmcc.2010.11.016 |
0.749 |
|
| 2010 |
Maas JE, Wan TC, Figler RA, Gross GJ, Auchampach JA. Evidence that the acute phase of ischemic preconditioning does not require signaling by the A 2B adenosine receptor. Journal of Molecular and Cellular Cardiology. 49: 886-93. PMID 20797398 DOI: 10.1016/J.Yjmcc.2010.08.015 |
0.798 |
|
| 2010 |
van der Hoeven D, Gizewski ET, Auchampach JA. Activation of the A(3) adenosine receptor inhibits fMLP-induced Rac activation in mouse bone marrow neutrophils. Biochemical Pharmacology. 79: 1667-73. PMID 20149782 DOI: 10.1016/j.bcp.2010.02.002 |
0.759 |
|
| 2010 |
Ge ZD, van der Hoeven D, Maas JE, Wan TC, Auchampach JA. A(3) adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells. Journal of Molecular and Cellular Cardiology. 49: 280-6. PMID 20132822 DOI: 10.1016/J.Yjmcc.2010.01.018 |
0.783 |
|
| 2010 |
Auchampach JA, Gizewski ET, Wan TC, de Castro S, Brown GG, Jacobson KA. Synthesis and pharmacological characterization of [(125)I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor. Biochemical Pharmacology. 79: 967-73. PMID 19917269 DOI: 10.1016/J.Bcp.2009.11.009 |
0.509 |
|
| 2009 |
Kreckler LM, Gizewski E, Wan TC, Auchampach JA. Adenosine suppresses lipopolysaccharide-induced tumor necrosis factor-alpha production by murine macrophages through a protein kinase A- and exchange protein activated by cAMP-independent signaling pathway. The Journal of Pharmacology and Experimental Therapeutics. 331: 1051-61. PMID 19749080 DOI: 10.1124/Jpet.109.157651 |
0.771 |
|
| 2009 |
Auchampach JA, Kreckler LM, Wan TC, Maas JE, van der Hoeven D, Gizewski E, Narayanan J, Maas GE. Characterization of the A2B adenosine receptor from mouse, rabbit, and dog. The Journal of Pharmacology and Experimental Therapeutics. 329: 2-13. PMID 19141710 DOI: 10.1124/Jpet.108.148270 |
0.719 |
|
| 2008 |
Liou GI, Auchampach JA, Hillard CJ, Zhu G, Yousufzai B, Mian S, Khan S, Khalifa Y. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Investigative Ophthalmology & Visual Science. 49: 5526-31. PMID 18641283 DOI: 10.1167/iovs.08-2196 |
0.366 |
|
| 2008 |
van der Hoeven D, Wan TC, Auchampach JA. Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. Molecular Pharmacology. 74: 685-96. PMID 18583455 DOI: 10.1124/mol.108.048066 |
0.779 |
|
| 2008 |
Melman A, Gao ZG, Kumar D, Wan TC, Gizewski E, Auchampach JA, Jacobson KA. Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorganic & Medicinal Chemistry Letters. 18: 2813-9. PMID 18424135 DOI: 10.1016/J.Bmcl.2008.04.001 |
0.505 |
|
| 2008 |
Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, Gross GJ, Kwok WM, Auchampach JA. The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. The Journal of Pharmacology and Experimental Therapeutics. 324: 234-43. PMID 17906066 DOI: 10.1124/Jpet.107.127480 |
0.433 |
|
| 2006 |
Ge ZD, Peart JN, Kreckler LM, Wan TC, Jacobson MA, Gross GJ, Auchampach JA. Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor. The Journal of Pharmacology and Experimental Therapeutics. 319: 1200-10. PMID 16985166 DOI: 10.1124/Jpet.106.111351 |
0.814 |
|
| 2006 |
Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proceedings of the National Academy of Sciences of the United States of America. 103: 7895-900. PMID 16672367 DOI: 10.1073/Pnas.0511232103 |
0.385 |
|
| 2006 |
Kreckler LM, Wan TC, Ge ZD, Auchampach JA. Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. The Journal of Pharmacology and Experimental Therapeutics. 317: 172-80. PMID 16339914 DOI: 10.1124/Jpet.105.096016 |
0.8 |
|
| 2004 |
Auchampach JA, Jin X, Moore J, Wan TC, Kreckler LM, Ge ZD, Narayanan J, Whalley E, Kiesman W, Ticho B, Smits G, Gross GJ. Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. The Journal of Pharmacology and Experimental Therapeutics. 308: 846-56. PMID 14634049 DOI: 10.1124/Jpet.103.057943 |
0.787 |
|
| 2003 |
Ticho B, Whalley E, Gill A, Lutterodt F, Jin X, Auchampach J, Smits G. Renal effects of BG9928, an A1 adenosine receptor antagonist, in rats and nonhuman primates Drug Development Research. 58: 486-492. DOI: 10.1002/Ddr.10176 |
0.408 |
|
| 2002 |
Cross HR, Murphy E, Black RG, Auchampach J, Steenbergen C. Overexpression of A(3) adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. American Journal of Physiology. Heart and Circulatory Physiology. 283: H1562-8. PMID 12234810 DOI: 10.1152/Ajpheart.00335.2002 |
0.41 |
|
| 2002 |
Fryer RM, Auchampach JA, Gross GJ. Therapeutic receptor targets of ischemic preconditioning. Cardiovascular Research. 55: 520-5. PMID 12160948 DOI: 10.1016/S0008-6363(02)00316-4 |
0.317 |
|
| 2002 |
Black RG, Guo Y, Ge ZD, Murphree SS, Prabhu SD, Jones WK, Bolli R, Auchampach JA. Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. Circulation Research. 91: 165-72. PMID 12142350 |
0.373 |
|
| 2000 |
Gumina RJ, Auchampach J, Wang R, Buerger E, Eickmeier C, Moore J, Daemmgen J, Gross GJ. Na(+)/H(+) exchange inhibition-induced cardioprotection in dogs: effects on neutrophils versus cardiomyocytes. American Journal of Physiology-Heart and Circulatory Physiology. 279. PMID 11009442 DOI: 10.1152/Ajpheart.2000.279.4.H1563 |
0.319 |
|
| 1997 |
Maldonado C, Qiu Y, Tang XL, Cohen MV, Auchampach J, Bolli R. Role of adenosine receptors in late preconditioning against myocardial stunning in conscious rabbits American Journal of Physiology-Heart and Circulatory Physiology. 273. PMID 9321822 DOI: 10.1152/Ajpheart.1997.273.3.H1324 |
0.339 |
|
| Show low-probability matches. |